Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 7/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 6/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197139 | 1.00 | SLC7A5 (0.48) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| SCHEMBL196695 | 1.00 | SLC7A5 (0.48) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Ammonia Solution, Strong SCHEMBL28728215 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Hydrochloric Acid SCHEMBL21059082 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Chloromethane SCHEMBL29259265 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Hydrochloric Acid SCHEMBL28431532 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Hydrochloric Acid SCHEMBL18770586 | 0.97 | SLC7A5 (0.46) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Trifluoroacetic Acid SCHEMBL4576488 | 0.89 | GRB2 (0.42) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Trifluoroacetic Acid SCHEMBL27695113 | 0.89 | GRB2 (0.42) | SLC7A5PTGS1SLC7A11GRIK1SLC1A2 | |
| Leucine SCHEMBL9119565 | 0.87 | SLC7A5 (0.72) | SLC7A5GRIK1SLC1A2SLC1A3SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 743 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117529489-A | Bicyclic peptide ligands specific for NK cells | 拜斯科技术开发有限公司 | 2024-02-06 | — | — | CN | claimed |
| US-20240010684-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2024-01-11 | — | — | US | claimed |
| EP-4240750-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-09-13 | — | — | EP | claimed |
| CN-115957294-A | Beneficial effects of supplementation with N-acetylcysteine and glycine to improve glutathione levels | 贝勒医学院 | 2023-04-14 | — | — | CN | claimed |
| CN-115572237-A | Preparation method of L-alpha-neopentyl glycine | 苏州爱玛特生物科技有限公司 | 2023-01-06 | — | — | CN | claimed |
| EP-4011904-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-06-15 | — | — | EP | claimed |
| WO-2022096394-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | WO | claimed |
| WO-2022080385-A1 | PEPTIDE, AND MODIFICATION OF ANTIBODY WITH PEPTIDE | 国立大学法人京都大学 | 2022-04-21 | — | — | WO | claimed |
| EP-3966226-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | claimed |
| EP-3752174-A1 | FIBROBLAST GROWTH FACTOR ANALOGS AND USES THEREOF | University of Florida Research Foundation, Incorporated (US) | 2020-12-23 | — | — | EP | claimed |
| US-6255286-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ALZHEIMER'S DISEASE | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2001-07-03 | — | — | US | claimed |
| US-6252041-B1 | Depsipeptides containing non-natural amino acids | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2001-06-26 | — | — | US | claimed |
| US-6211145-B1 | PRODUCTION OF APOLYPOPROTEIN E | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2001-04-03 | — | — | US | claimed |
| EP-0967222-A1 | CYCLIC DEPSIPEPTIDES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Nisshin Flour Milling Co., Ltd. (JP) | 1999-12-29 | — | — | EP | claimed |
| US-6001815-A | ALZHEIMER'S DISEASE; ANTILIPEMIC AGENT | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1999-12-14 | — | — | US | claimed |
| EP-0960885-A1 | DEPSIPEPTIDES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Nisshin Flour Milling Co., Ltd. (JP) | 1999-12-01 | — | — | EP | claimed |
| EP-0934952-A2 | Peptides containing an N-substituted glycine residue | Nisshin Flour Milling Co., Ltd. (JP) | 1999-08-11 | — | — | EP | claimed |
| EP-0931792-A1 | Depsipeptides containing non-natural amino acids | Nisshin Flour Milling Co., Ltd. (JP) | 1999-07-28 | — | — | EP | claimed |
| EP-0927723-A1 | Bicyclic depsipeptides promoting the production of apolipoprotein E | Nisshin Flour Milling Co., Ltd. (JP) | 1999-07-07 | — | — | EP | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240010684-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SPINT2, SERPINB1 | SLC7A5 3190/4885PTGS1 1400/4885SLC7A11 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.